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Purpose: The authors recently reported the development of a noninvasive diagnostic assay 
using urinary matrix metalloproteinases (MMPs) as monitors of disease-free status and  bladder 
cancer in high-risk populations. Using an approach called clinical intervention determining 
diagnostic (CIDD), they identified with high confidence those patients who could be excluded 
from additional intervention. To maximize performance, MMPs were combined with DNA-
based markers and CIDD was applied to a population of patients undergoing monitoring for 
recurrence.
Patients and methods: Urine samples were obtained from 323 patients, 48 of whom had 
a recurrence and 275 of whom did not have cancer upon cytoscopic evaluation. Twist1 and 
Nid2 methylation status was determined using methylation-specific polymerase chain reaction, 
FGFR3 mutational status by quantitative PCR, and MMP levels by enzyme-linked immuno-
sorbent assay.
Results: Using a combination of these DNA and protein markers, the authors identified with 
high confidence (97% negative predicted value) those patients who do not have cancer. Cutoffs 
were adjusted such that at 92% sensitivity, 51% of disease-free patients might be triaged from 
receiving further tests.
Conclusion: The multi-analyte diagnostic readout assay described here is the first to com-
bine protein and DNA biomarkers into one assay for optimal clinical performance. Using this 
approach, the detection of FGFR3 mutations and Twist1 and Nid2 methylation in the urine of 
patients undergoing bladder cancer recurrence screening increase the sensitivity and negative 
predictive value at an established MMP protein cutoff. This noninvasive urinary diagnostic assay 
could lead to the more efficient triage of patients undergoing recurrence monitoring.
Keywords: matrix metalloproteinase, FGFR3, bladder cancer, diagnostics
Introduction
In 2007, over 67,000 new cases of bladder cancer were diagnosed in the USA.1 Bladder 
cancer is the most costly of all cancers per patient, with average total costs ranging 
from $69,287 to $202,203.2 Biomarkers with high specificity and sensitivity have the 
potential to significantly reduce costs, particularly because the prevalence of cancer 
in a population of patients undergoing routine evaluation for recurrence is low at any 
monitoring interval. To date, most noninvasive diagnostic assays are based upon sta-
tistical averaging over a large number of patients in order to arrive at thresholds that 
maximize sensitivity and specificity. In practice, performance characteristics of assays 
utilizing sensitivity and specificity allow a physician to determine a patient’s relative 
risk with a certain degree of statistical confidence, but these assays can create ambiguity 
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as to the desired course of management. Currently available 
biomarkers suffer from both low sensitivity and low speci-
ficity, particularly for low-grade tumors.3 This l imitation is 
of importance when utilizing biomarkers for triaging high-
risk populations such as bladder cancer survivors where 
single markers are unlikely to provide clinically relevant 
results.4 There is a clear need for novel clinical management 
approaches and assays that result in more efficient screening 
and management of high-risk patients.
Matrix metalloproteinases (MMPs) are a family of zinc-
dependent endopeptidases that have been shown to be key 
regulators of tumor growth, angiogenesis, and  metastasis 
formation.5,6 Increased MMP expression is required for tumors 
to grow into the surrounding tissue and for the  dissemination 
of metastatic cells into the vasculature and distant sites. 
 Detection of MMPs in the urine of cancer patients has been 
shown to correlate with disease status in a variety of cancers,7–11 
including bladder cancer.7,9,12 This study and others like it have 
shown that biologically active MMP-2 and MMP-9 are found 
at higher levels and at greater frequency in the urine of cancer 
patients than in that of asymptomatic healthy controls.
In a recent study, the authors reported the development 
of a noninvasive diagnostic assay utilizing urinary MMPs as 
monitors of disease-free status and cancer in high-risk bladder 
cancer populations.12 The report outlined the use of urinary 
MMPs (either MMP-2 or MMP-9) as triage monitors to man-
age the care of high-risk populations by identifying with high 
confidence those patients who do not have  bladder cancer. 
In their previous report, the authors described a  clinical 
approach based on high negative predictive value (NPV), 
termed the clinical intervention determining  diagnostic 
(CIDD), that can reduce ambiguity by identifying patients 
who do not have bladder cancer, stratifying the population 
into patients who should receive standard-of-care monitoring 
and patients who could potentially forgo cystoscopy.12
To complement their existing protein-based assay and 
increase performance in high-risk populations, the authors 
have developed noninvasive DNA-based assays for the 
detection of FGFR3 mutations and Twist1/Nid2  methylation 
in urine. Mutations of the FGFR3 gene have been observed 
in both bladder and cervical neoplasias.13 FGFR3 is a 
member of a family of four structurally related tyrosine 
kinase  glycoprotein receptors encoded by separate genes.14 
FGFR3 mutations in bladder tumors have been  characterized 
in exon 7, exon 10, and exon 15, and show a significant 
association with low-grade, noninvasive tumors.15–18
While FGFR3 mutations occur primarily in  low-grade 
noninvasive tumors and MMPs are associated with 
 higher-grade invasive tumors, methylation of Twist1 and 
Nid2 is not associated with tumor stage. Twist1 and Nid2 
have been frequently shown to be methylated in various 
cancers including bladder cancer.19–22 A recent study has 
also shown that, together, the methylation status of Twist1 
and Nid2 can be used as independent predictors of bladder 
cancer in urine samples.23
The addition of DNA markers to the existing  protein-based 
assay results in superior performance. DNA markers, which 
tend to have high specificity, increase sensitivity without 
much loss of specificity. This allows the protein marker cut-
offs to be set at higher levels, increasing specificity without 
loss of sensitivity and NPV.
Using these markers and the CIDD concept, patients with 
MMP levels below the cutoffs could be potentially excluded 
from further intervention. The assay described here combines 
MMP-2, FGFR3 mutation detection and Twist1/Nid2 methy-
lation analysis in one noninvasive test. This multi-analyte 
diagnostic readout (MADR) assay allows for the more efficient 
management of high-risk bladder cancer populations by poten-
tially reducing the number of negative cystoscopies.
Materials and methods
Experimental samples
Urine samples were collected from various academic 
 institutions and urology practices. All sites participating 
received Institutional Review Board approval. Subjects 
were required to sign institutional review board-approved 
informed consents, prior to any study-related procedures 
being performed. All patients had previously been treated 
for bladder cancer and were undergoing routine monitor-
ing for recurrence. Urine samples were collected using a 
standard clean catch protocol from 323 patients, including 
48 patients identified by various means to have a bladder 
cancer recurrence (all tumors confirmed by pathology) and 
275 patients who had no evidence of disease at the given 
monitoring interval. Table 1 describes the clinical charac-
teristics of the test populations including stage and grade of 
the cancer samples. Urine samples were aliquoted and stored 
at −80°C until assayed. For DNA analyses, urine samples 
were stabilized with 25 mM EDTA prior to aliquoting and 
freezing.
MMP-2 and MMP-9 ELISA
To determine total MMP-2 and MMP-9 levels, 50 mL 
or 100 mL of neat urine, respectively, were processed 
through ELISAs specific for MMP-2 or MMP-9, as per the 
 manufacturer’s instructions (R&D Systems, Minneapolis, MN). 
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All assays were performed blinded as to the clinical status of 
the samples.
DNA isolation from urine
DNA isolation was performed from whole urine to purify 
both cell-associated and free DNA. Urine aliquots were 
thawed at room temperature, and genomic DNA isolation 
was performed using the QIAamp Minelute Virus Vacuum 
Kit according to manufacturer’s instructions. Purified DNA 
was eluted in 150 ul AVE elution buffer or water and stored 
at −20°C until ready to assay.
FGFR3 exon-specific amplification 
(primary PCR)
Primary PCR of genomic DNA extracted from 4 mL of urine 
was carried out using oligonucleotide primers specific for human 
FGFR3 to amplify DNA from exons 7, 10, and 15 (Table 2).
PCR amplification was performed using a C1000 thermal 
cycler (Bio-Rad Laboratories, Hercules, CA) under standard 
conditions. DNA amplification was confirmed by agarose gel 
analysis of primary PCR products.
FGFR3 mutation detection
FGFR3 mutations were detected by utilizing a  PCR- clamping 
methodology. Wild-type blocking oligonucleotides  containing 
locked nucleic acid (LNA) bases surrounding known  mutation 
Table 1 The clinical characteristics of the test populations
Controls Number of patients
NED 275
Cancers 48
Stage
Ta 31
Tis 4
T1 9
T2 2
T3 2
Grade
1 26
2 5
3 17
Abbreviation: NED, no evidence of disease.
Table 2
Assay Reagent Sequence
FGFR3  
primary PCR
Exon 7 forward 5′ GCG GTC CCA AAA GGG TCA GTA CAG TGG CGG TGG TGG TGA GGG AG 3′
Exon 7 reverse 5′ GCG GTC CCA AAA GGG TCA GTA CGC ACC GCC GTC TGG TTG G 3′
Exon 10 forward 5′ GCG GTC CCA AAA GGG TCA GTA CGG TCT GGC CCT CTA GAC TCA 3′
Exon 10 reverse 5′ GCG GTC CCA AAA GGG TCA GTA CGG TCT GGC CCT CTA GAC TCA 3′
Exon 15 forward 5′ GCG GTC CCA AAA GGG TCA GTA CCC TGC CCT GAG ATG CT 3′
Exon 15 reverse 5′ GCG GTC CCA AAA GGG TCA GTA CCG TCC TAC TGG CAT GAC C 3′
FGFR3 mutation 
detection
Exon 7 forward 5′ GCG TCA TCT GCC CCC A 3′
Exon 7 reverse 5′ CAC CGC CGT CTG GTT G 3′
Exon 7 LNA 5′ AGA GCG CTC CCC G 3′
Exon 7 probe 5′ FAM-CCC GCC TGC AGG ATG GGC CGG T-lowa black FQ 3′
Exon 10 forward 5′ GGC CTC AAC GCC CAT GT 3′
Exon 10A reverse 5′ TAG CTG AGG ATG CCT GCA TA 3′
Exon 10B reverse 5′ CCG TAG CTG AGG ATG CCT G 3′
Exon 10A LNA 5′ ATA CAC ACT GCC CGC CT 3′
Exon 10B LNA 5′ GCC TGC ATA CAC ACT 3′
Exon 10 probe 5′ FAM-CCG AGG AGG AGC TGG TGG AGG CTG AC-lowa black FQ 3′
Exon 15 forward 5′ CAA TGT GCT GGT GAC CGA G 3′
Exon 15 reverse 5′ CCG GGC TCA CGT TGG TC 3′
Exon 15 LNA 5′ GGT CGT CTT CTT GTA GT 3′
Exon 15 probe 5′ FAM-CTG GCC CGG GAC GTG CAC AAC CTC GAC T-lowa black FQ 3′
Twist/Nid Twist forward 5′ GTT AGG GTT CGG GGG CGT TGT T 3′
Twist reverse 5′ CCG TCG CCT TCC TCC GAC GAA 3′
Nid forward 5′ GCG GTT TTT AAG GAG TTT TAT TTT C 3′
Nid reverse 5′ CTA CGA AAT TCC CTT TAC GCT 3′
ACTB ACTB forward 5′ TAG GGA GTA TAT AGG TTG GGG AAG TT 3′
ACTB reverse 5′ AAC ACA CAA TAA CAA ACA CAA ATT CAC 3′
ACTB zen probe 5′ TGG GGT GGT/ZEN/GAT GGA GGA GGT TTA GTA AGT TTT TT 3′
Abbreviations: ACTB, Actin-b; PCR, polymerase chain reaction.
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sites were included along with real-time PCR primers and 
dual-labeled Taqman probes. Real-time PCR amplification 
was performed using a Light Cycler real-time thermal cycler 
(Roche Diagnostics Corporation,  Indianapolis, IN). Dual real-
time PCR reactions, with and without the LNA blocker, were 
assembled in duplicate for each amplification. Positive control 
plasmids were designed to incorporate the region of the muta-
tion, as well as flanking sequences to facilitate amplification 
of the positive control plasmid during the primary PCR step 
described above. Each positive control plasmid contains a 
single nucleotide change, confirmed by sequencing.
Twist1/Nid2 methylation detection
Detection of methylated Twist1 and Nid2 was carried out by 
conventional methylation specific PCR. For this assay, DNA 
from 8 mL of urine was extracted as described above and 
eluted in water. DNA yield was determined by  quantitative 
real-time PCR using a reference gene. A maximum of 2 ug 
of DNA was concentrated using AES 1000 Speed Vac 
(Thermo Fisher, Waltham, MA). Each sample was resus-
pended in water by pipetting. Bisulfite conversion of the DNA 
was performed using a Qiagen Epitect Bisulfite Kit following 
the manufacturer’s directions. The resulting converted DNA 
was loaded on columns, subjected to desulfonation, washed, 
and eluted in 30 µL of molecular grade water and placed 
at −20°C until assayed.
Conventional MSP was performed using methylation-
specific primers to sequences within the promoter 
region of Twist1 and Nid2. The primer sequences are 
as listed in Table 2.
PCR amplifications were performed using the C1000 
thermocycler under standard conditions. Each set of 
 amplifications contained a water blank, unconverted human 
genomic DNA, 100% methylated DNA, 100% unmethylated 
DNA, and a 1% methylated DNA control.
In addition, to verify that negative samples had the 
required minimum of 10 ng DNA content, 5 µL of bisulfite-
converted DNA was quantitated by qPCR using primers 
specific for a nonmethylated region of Actin-B (Table 2). 
Actin-B quantitation was determined using a standard curve of 
unmethylated DNA (Qiagen), ranging from 0.4 to 50 ng total 
input. Real-time PCR amplifications were carried out with the 
Roche LightCycler 480 under standard conditions.
Biomarker performance analysis  
using MADR
Samples positive for FGFR3 were assigned a score of “1,” 
while those negative for an FGFR3 mutation were assigned 
a score of “0.” For quantitative markers, individual marker 
cutoffs were established to maximize specificity. Each 
marker was then scored as “1” for above the cutoff or “0” 
for below the cutoff. The sum of all markers was used to 
establish final clinical performance. By assigning an indi-
vidual score for each marker, DNA and protein markers are 
easily combined without the need of complex multivariate 
analyses. To obtain maximum negative predictive value, 
samples are considered negative when a total score of “0” 
is obtained. Patients with scores of “0” could be excluded 
from further testing with very high NPV. Samples with score 
of $“1” are  considered  intermediate and, based on the CIDD 
concept, should remain in cue for standard of care. Final 
clinical performance of  sensitivity, specificity, and NPV 
were calculated using  standard methods. Confidence intervals 
were calculated using an excel macro binomial confidence 
interval calculator.
Results
MMP-2 detection in urine  
and performance using CIDD
The CIDD approach uses quantitative markers to triage 
patient populations. Using this approach, marker cutoffs 
are set to result in maximum NPV and sensitivity, such that 
patients who do not have cancer might be excluded from 
further intervention (Figure 1A). Patients could also have 
been triaged into those that might benefit from maximum 
intervention (high positive predictive value).
In the authors’ previous study, they described the use of 
MMPs as bladder cancer markers in a population consist-
ing of bladder cancer patients and asymptomatic controls.12 
In this study, they determined MMP levels in a bladder 
cancer  recurrence population using MMP specific ELISAs. 
In this clinical population, MMP-2 resulted in better clini-
cal performance than MMP-9 (data not shown) and was 
therefore used in the MADR assay. As in previous  studies, 
mean MMP-2 levels are higher in patients with cancer than 
in those with no evidence of disease (1.337 ng/mL and 
0.844 ng/mL,  respectively). However, in this high-risk patient 
group, the distribution of cancer and cancer-free patients 
is not as d istinct, such that in order to achieve high NPV 
($90%) with high sensitivity ($90%), protein cutoff values 
would have to be set lower than in asymptomatic populations 
(Figure 1B). In a recurrence monitoring population, MMP-2 
cutoffs that result in $90% NPV and sensitivity result in 
only 19% of the cancer-free population being excluded from 
further intervention.
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MADR: combining protein  
and DNA markers
Although protein marker levels can be set to maximize 
 sensitivity ($90%), as shown above, this often results in loss 
of specificity. In contrast, DNA markers tend to have high 
 specificity, but sensitivities much lower than 90%. The authors 
have developed a method for combining binary marker results 
(as in the case of DNA markers) with  quantitative markers (as 
in the case of protein markers) to maximize sensitivity and 
NPV in a population of patients undergoing monitoring for 
bladder cancer recurrence. The combination of DNA markers 
with protein markers  effectively cherry-picks the population of 
cancers such that when a protein marker is applied, higher cut-
offs can be applied, thus maximizing specificity (Figure 2).
Real time FGFR3 mutation detection  
in patient urine samples
This report uses LNA technology and real-time PCR for 
assessing the mutation status of FGFR3 in urine samples from 
patients undergoing recurrence monitoring. Primary amplifica-
tions of exons 7, 10, and 15 were  performed as described 
above. An additional quantitative PCR  reaction to a refer-
ence gene was also performed to determine the amount of 
amplifiable DNA in each sample. Given the high likelihood of 
Figure 1 Clinical intervention determining diagnostic (CIDD) approach using matrix metalloproteinases (MMPs). (A) The CIDD approach uses one MMP cutoff to maximize 
sensitivity (Sens) and negative predictive value (NPV), and a second cutoff to maximize specificity (Spec) and positive predictive value (PPV). Patients with cutoff values in 
between these cutoffs continue to receive standard of care. (B) In high-risk populations, the MMP levels in the cancer and cancer-free populations have greater overlap, such 
that MMP cutoffs would have to be lowered to retain high NPV and sensitivity.
Abbreviations: PPV, positive predictive value; NPV, negative predictive value.
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DNA degradation that could occur in the urine environment, 
this step was critical in determining that a  minimum DNA 
input for each sample was used for mu tation detection. Out 
of 323 samples tested, seven did not have enough DNA to 
reliably obtain an FGFR3 result. These s amples were tagged 
as “inconclusive” and were removed from the final data 
analysis. Mutation  detection was  performed on the remain-
ing 316 samples using PCR-clamping with LNAs to block 
wild-type sequences. LNA is a nucleic acid analogue that 
enhances hybridization affinity towards complementary DNA 
and RNA.24 Several studies have applied LNA to nucleic 
acid diagnostics, including the unambiguous detection of 
single-nucleotide polymorphisms.25,26
Real-time PCR amplifications were carried out using 
the primary PCR products from each patient sample. Each 
sample was amplified in duplicate in the presence and 
absence of LNA blocking oligonucleotide (green lines, 
Figure 3). A representative real-time PCR amplification of 
a patient sample positive for an FGFR3 mutation in exons 7 
is shown in Figure 3, top panel. The bottom trace depicts 
a single patient sample that is negative for FGFR3 muta-
tions in exon 7. In addition, control urine DNA (blue lines), 
Figure 2 Multi-analyte diagnostic readout: addition of DNA markers reduces population overlap and increases performance. (A) Given the very high specificity of DNA 
markers, any DNA marker-positive samples can be moved to the high-risk group. (B) This shift essentially depletes the cancer population, allowing higher protein marker 
cutoffs to be set, increasing specificity while retaining final assay sensitivity $ 90%. 
Abbreviations: PPV, positive predictive value; NPV, negative predictive value.
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Figure 3 FGFR3 mutation detection in the urine. 
Notes: DNA was extracted from the urine of patients undergoing recurrence monitoring and tested for the presence of FGFR3 mutations. Representative samples traces 
are shown above for a sample that was positive for an exon 7 mutation (C1723) and one that was negative for an exon 7 mutation (C1920). Each sample was amplified in 
the presence or absence of LNA blocking oligonucleotides (green lines) and run in duplicate. When a mutation is present, amplification curves are shifted to the left (arrow). 
Control DNA (blue lines) and control DNA with 1% mutant plasmid (red lines) were also amplified with and without LNA blocking oligonucleotides. 
Abbreviations: PCR, polymerase chain reaction; RFU, relative fluorescence units.
and control DNA with 1% mutant plasmid (red lines) were 
amplified with and without LNA blocking oligonucleotide. 
In the top panel, amplification of the patient sample (green) 
displays a shift to the left (arrow), similar to that seen with 
the 1% mutant plasmid controls (red), demonstrating the 
 presence of a mutation. In the bottom panel, the patient 
sample (green) amplifies similarly to the control urine DNA 
(blue), suggesting that no mutation is present in this sample. 
In this sample cohort, 15 mutations were detected, five in 
the urine of cancer patients, resulting in 10% sensitivity 
with 96% specificity. To verify these results, the mutations 
detected in the urine of cancer patients were confirmed by 
direct amplicon sequencing.
Twist1/Nid2 methylation detection
The Twist1/Nid2 methylation detection assay presented here 
utilizes DNA extracted from 8 mL of whole urine.  Methylation 
status was determined using conventional methylation spe-
cific PCR for both Twist1 and Nid2. In these assays, 1% 
methylated DNA can be reliably detected in as little as 10 ng 
of converted DNA. To determine that a minimum of 10 ng 
of converted DNA was assayed for each reaction, bisulfite 
converted DNA was quantitated using real-time  amplification 
of Actin-B.
Since the bisulfite conversion reaction has a maximum 
input of 2 ug of DNA, real-time PCR was used prior to 
conversion to determine total yield from urine. A maximum 
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of 2 ug per sample was added to the conversion reaction. 
Twist1 and Nid2 methylation-specific PCR products were 
detected at ∼120 and ∼140 bp, respectively. Unmethylated 
DNA was used as a negative control, while 1% methylated 
DNA mix was used as a positive control in each reaction. 
Representative gels are shown in Figure 4.  Methylation 
thresholds for Twist1 and Nid2 were established by 
densitometry. The cutoffs derived from these analyses 
were used to determine positive samples. At the established 
cutoffs, Twist1 methylation was detected in 36 cancer 
samples and 82 controls, resulting in 75% sensitivity with 
69% specificity. Nid2 methylation was detected in 22 cancer 
samples and 26 controls, resulting in 46% sensitivity with 
90% specificity.
MADR: combining protein  
and DNA markers
Using the MADR approach, threshold and cutoff marker 
levels were set so that individual marker performance 
is inconsequential, but that in combination, maximum 
clinical performance is achieved. For example, although 
i ndividually FGFR3 and Nid2 sensitivities are low, 
s pecificity for both markers was high. No single DNA 
marker achieved $90% sensitivity, but since these markers 
did not overlap, in combination they increase sensitivity 
without much loss of specificity. In this fashion, to obtain 
maximum NPV at high sensitivity, the authors first applied 
binary markers, and then established cutoffs for the other 
markers. In combination, patients negative for all markers 
at the  established cutoffs could be excluded from further 
intervention (power of exclusion). Given that the prevalence 
of cancer in any given population is low, high NPV may be 
achieved even with low sensitivity. The CIDD approach 
requires high sensitivity to add confidence that few, if any, 
cancers would be missed. The addition of highly specific 
DNA markers increased sensitivity such that MMP-2 cutoff 
levels could be raised. This effectively maintained high 
sensitivity while increasing specificity (Table 3).
In this recurrence monitoring population, the c ombination 
of all four markers as described above resulted in 
97.4% NPV at a sensitivity of 92% and the possibility of 
excluding 51% of patients who do not have cancer from 
receiving further tests (Table 3). Importantly, the three false 
negative samples observed here were all of low stage and 
Figure 4 Twist1/Nid2 methylation detection in urine. 
Notes: DNA was extracted from 8 mL of urine and processed to determine methylation of the Twist1 and Nid2 genes using methylation-specific polymerase chain reaction. 
Methylation thresholds were established using densitometry. Representative gels for Twist1 and Nid2 are shown above. 
Abbreviation: NED, no evidence of disease.
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Table 3 MADR results in maximum clinical performance
Markers Cutoffs NPV* Sensitivity Power of exclusion
MMP-2 MMP-2 , 0.309 ng/mL 91.7% 90% 
(43/48) 
[77%–97%]
19% 
(51/268) 
[15%–24%]
MMP-2 + Nid2 MMP-2 , 0.418 ng/mL 
Nid2 , 600 k
93.6% 90% 
(43/48) 
[77%–97%]
26% 
(71/268) 
[21%–32%]
MMP-2 + Nid2 + FGFR3 MMP-2 , 0.456 ng/mL  
Nid2 , 600 k
94.3% 90% 
(43/48) 
[77%–97%]
29% 
(77/268) 
[23%–35%]
MMP-2 + Nid2 + FGFR3 + Twist1 MMP-2 , 1.100 ng/mL 
Nid2 , 600 k 
Twist1 , 249 k
97.4% 92% 
(44/48) 
[80%–98%]
51% 
(136/268) 
[44%–57%]
Notes: Urine samples from 48 individuals with bladder cancer and 268 NED patients were tested for MMP-2, FGFR3, Twist1, and Nid2. High specificity of the DNA markers 
allowed for higher MMP-2 cutoffs to be set as each DNA marker was added, increasing specificity and NPV. Although individually low, in combination the four markers results 
in 92% sensitivity with the power to exclude 51% of cancer-free patients from further intervention with very high confidence (97.4% NPV).
Abbreviations: MMP, matrix metalloproteinases; NPV, negative prediction value; NED, no evidence of disease.
grade (TaG1). At 92% sensitivity, of all patients (cancers and 
controls) being monitored at any given time, 43% would be 
triaged from receiving further tests.
Discussion
This study describes the development of a noninvasive 
diagnostic test for the triaging of patients being evaluated for 
potential bladder cancer recurrence. The assay presented here 
combines the sensitivity of protein markers with the specific-
ity of DNA markers for optimum clinical performance. Here, 
MMP-2 protein levels are coupled with methylation analysis 
of the Twist1 and Nid2 genes and mutational analysis of the 
FGFR3 gene. Using this approach, 51% of patients being 
monitored for bladder cancer recurrence, but who do not 
have cancer, could have been excluded from further invasive 
intervention with very high confidence (97% NPV) (Table 3). 
The MADR approach builds on the CIDD concept the authors 
have previously described.12 Using CIDD, patients would be 
stratified into three groups: one that is cancer free and could 
be excluded from undergoing further evaluation; a second 
that simply receives the already scheduled standard of care; 
and a third that has a high likelihood of cancer and could 
receive accelerated intervention.
FGFR3 mutations are prevalent in noninvasive, low-grade 
bladder tumors.15–18 Although sensitivity for FGFR3 alone was 
low in this sample set (11%), the presence of an FGFR3 muta-
tion is indicative of a high likelihood of cancer. Given the 
high specificity of FGFR3 mutations to bladder cancer, 
FGFR3 mutations in urine could be used to establish a group of 
patients who are at high risk and who could benefit from accel-
erated intervention. In addition, studies have further shown 
that patients who had a negative cystoscopy but a positive 
FGFR3 mutation in urine at any one monitoring interval are 
often have recurrent cancer in subsequent visits.27
The authors have previously demonstrated how MMPs can 
be used to separate bladder cancer patients from cancer-free 
controls, as depicted in Figure 1A. Although the specific-
ity in these studies was high, specificity drops in high-risk 
populations as MMP levels converge. Given the potential high 
specificity of DNA markers, the addition of these markers to 
the existing protein marker distribution essentially depletes 
the cancers from the population to which the protein marker 
is applied (Figure 2A). Since the number of cancers that 
overlap with the cancer-free individuals is reduced, the pro-
tein marker cutoff can then be shifted, resulting in increased 
specificity (Figure 2B). As the assay continues to be improved, 
other validated bladder cancer markers with high specificity 
could be added and others removed to continue to increase 
performance with a minimum number of  markers. In the study 
presented here, the application of MADR using these bladder 
cancer markers in patients undergoing recurrence monitoring 
establishes new threshold levels that provide information as to 
which patients might be excluded from invasive procedures 
at the given monitoring interval and those who might benefit 
from accelerated intervention. Traditionally, protein and DNA 
markers are multiplexed as independent marker sets but not 
combined into a protein and DNA multiplex format. Although 
protein markers can achieve high sensitivity due to their quan-
titative nature, they often fall short of the specificity required 
to add  clinical utility. Therefore, multiplexing of a significant 
number of protein markers (eg, protein-based expression pat-
terns) are used to increase specificity. In contrast, independent 
DNA alterations tend to have high specificity, but require 
 significant multiplexing to achieve high sensitivity ($90%). 
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The current study demonstrates that the unique combination 
of DNA and protein markers into one assay improved clinical 
performance with a minimal number of markers resulting in 
lower assay complexity. The resulting diagnostic assay is the 
first to combine the best performance characteristics of protein 
biomarkers and DNA biomarkers into one assay for optimal 
clinical performance.
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